Table 1:
Updated characteristics of the study population (modified intention-to-treat population)*
| TOSCA (N=2391) |
SCOT (N=3983) |
IDEA France (N=2010) |
CALGB/SWOG 80702 (N=2452) |
HORG (N=708) |
ACHIEVE (N=1291) |
Total (N=12835) |
|
|---|---|---|---|---|---|---|---|
| Tumor stage, no. (%) | |||||||
| T1 | 76 (3.2%) | 128 (3.2%) | 78 (3.9%) | 140 (5.8%) | 1 (0.1%) | 75 (5.8%) | 498 (3.9%) |
| T2 | 236 (10.0%) | 333 (8.4%) | 161 (8.0%) | 298 (12.3%) | 60 (8.5%) | 119 (9.2%) | 1207 (9.4%) |
| T3 | 1763 (74.5%) | 2347 (58.9%) | 1399 (69.6%) | 1623 (66.8%) | 549 (77.8%) | 734 (56.9%) | 8415 (65.8%) |
| T4 | 290 (12.3%) | 1174 (29.5%) | 372 (18.5%) | 368 (15.2%) | 96 (13.6%) | 363 (28.1%) | 2663 (20.8%) |
| Missing data | 24 | 0 | 0 | 23 | 2 | 0 | 49 |
| Nodal stage, no. (%) | |||||||
| N1 | 1745 (73.2%) | 2749 (69.0%) | 1501 (74.8%) | 1792 (73.8%) | 472 (67.2%) | 959 (74.3%) | 9218 (72.0%) |
| N2 | 640 (26.8%) | 1233 (31.0%) | 506 (25.2%) | 637 (26.2%) | 230 (32.8%) | 332 (25.7%) | 3578 (28.0%) |
| Missing data | 6 | 1 | 3 | 23 | 6 | 0 | 39 |
| Risk group, no. (%) | |||||||
| Low risk (T1, T2, or T3 N1) | 1545 (65.3%) | 2032 (51.0%) | 1245 (62.0%) | 1551 (63.9%) | 416 (59.1%) | 718 (55.6%) | 7507 (58.7%) |
| High risk (T4, N2, or both) | 820 (34.7%) | 1950 (49.0%) | 764 (38.0%) | 878 (36.1%) | 288 (40.9%) | 573 (44.4%) | 5273 (41.3%) |
| Missing data | 26 | 1 | 1 | 23 | 4 | 0 | 55 |
| Primary tumor sidedness, no. (%) | |||||||
| Proximal | 934 (40.8%) | NA | 750 (42.6%) | 1278 (53.7%) | 313 (44.5%) | 491 (38.5%) | 3766 (44.8%) |
| Distal | 1358 (59.2%) | NA | 1012 (57.4%) | 1102 (46.3%) | 390 (55.5%) | 784 (61.5%) | 4646 (55.2%) |
| Missing data | 99 | 3983 | 248 | 72 | 5 | 16 | 4423 |
| Chemotherapy regimen, no. (%) | |||||||
| CAPOX | 833 (34.8%) | 2649 (66.5%) | 201 (10.0%) | 0 (0.0%) | 412 (58.2%) | 969 (75.1%) | 5064 (39.5%) |
| FOLFOX | 1558 (65.2%)† | 1334 (33.5%) | 1809 (90.0%) | 2452 (100.0%) | 296 (41.8%) | 322 (24.9%) | 7771 (60.5%) |
| Median follow-up time, months (Q1, Q3) | 84.3 (83.0-85.8) |
75.2 (74.2-76.1) |
79.5 (78.4-81.0) |
66.2 (65.1-67.1) |
79.7 (74.7-81.7) |
61.8 (61.3-62.7) |
72.3 (72.2-72.5) |
*
Percentages may not total 100 because of rounding. TOSCA Three or Six Colon Adjuvant, SCOT Short Course Oncology Treatment, IDEA International Duration Evaluation of Adjuvant, CALGB/SWOG Cancer and Leukemia Group B/Southwest Oncology Group, ACHIEVE denotes Adjuvant Chemotherapy for Colon Cancer with High Evidence, and HORG Hellenic Oncology Research Group, Therapy.
†
Patients in this trial received FOLFOX4; those in the other trials received modified FOLFOX6.